2021 Year in Review - HER2-Negative Breast Cancer
The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.
A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.
A Web-Based Survey on Suggested Modifications in the Management of Patients with Breast Cancer During the COVID-19 Pandemic
Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.
Real-World Patient-Reported Outcomes, Clinical Profile, and Treatment Patterns in a Subset of Patients with HR-Positive, HER2-Negative, Advanced Breast Cancer with Poor Prognostic Factors
In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.
Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis
Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer.
PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available.
CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status: A Real-World Evidence Study
A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology.
Olaparib Monotherapy in Germline BRCA Mutation–Positive, HER2-Negative Metastatic Breast Cancer in the Real-World Setting
Real-World Tumor Response of Palbociclib plus Letrozole versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
Patients with HR-positive, HER2-negative metastatic breast cancer are more likely to have disease response to palbociclib plus letrozole versus letrozole alone, according to a real-world study. However, in real-world practice, there is less information on the tumor response of palbociclib plus an aromatase inhibitor versus an aromatase inhibitor alone.
Page 1 of 3
Results 1 - 10 of 28
Results 1 - 10 of 28